Effect of Yong Chong Cao Capsule on Outcomes in Patients With Mild to Severe COPD

• Status: Unknown status
• Trial end date: 2020-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to evaluate the effectiveness of Yong Chong Cao capsule on outcomes in patients with mild to severe Chronic Obstructive Pulmonary Disease (COPD).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Henan University of Traditional Chinese Medicine
• Collaborator: Jiangsu Famous Medical Technology Co., Ltd.
• Treatments: Albuterol; Bromides; Fluticasone; Fluticasone Propionate, Salmeterol Xinafoate Drug Combination; Fluticasone-Salmeterol Drug Combination; Salmeterol Xinafoate; Tiotropium Bromide; Xhance

Criteria

Inclusion Criteria:

• A confirmed diagnosis of mild to severe COPD.

• Medically stable.

• Syndrome differentiation belongs to syndrome of insufficiency of qi of the lung and kidney.

• Age between 18 and 80 years.

• With the informed consent signed.

Exclusion Criteria:

• Pregnant or breast-feeding women.

• Current respiratory disorders other than COPD (e.g., bronchiectasis, bronchial asthma, tuberculosis, lung fibrosis, pulmonary thromboembolic, diffuse panbronchiolitis, lung cancer).

• Complicated with heart failure (NYHA Class III or IV), or myocardial infarction within six months ,or unstable hemodynamics.

• Complicated with serious hepatic and renal diseases (liver cirrhosis, portal hypertension, bleeding of varicose veins, dialysis, or renal transplantation).

• Any psychiatric condition rendering the patient unable to understand the nature, scope and possible consequences of the study.

• Participating in other trials or allergic to the used medicine.

• Participating in other clinical trials with other interventions in one month.

• Allergic to the used medicine.